Promyelocytic leukemia protein is required for gain of function by mutant p53

Cancer Research

Volumn 69, Issue 11, 2009, Pages 4818-4826

  Haupt, Sue ^a   Di Agostino, Silvia ^b   Mizrahi, Inbal ^c   Alsheich Bartok, Osnat ^c   Voorhoeve, Mathijs ^d   Damalas, Alex ^e   Blandino, Giovanni ^b   Haupt, Ygal ^a,c  

^a PETER MACCALLUM CANCER CENTRE   (Australia)

^b REGINA ELENA NATIONAL CANCER INSTITUTE   (Italy)

^c HEBREW UNIVERSITY   (Israel)

^d NATIONAL UNIVERSITY OF SINGAPORE   (Singapore)

^e UNIVERSITY OF IOANNINA   (Greece)

Author keywords

[No Author keywords available]

Indexed keywords

MUTANT PROTEIN; PROMYELOCYTIC LEUKEMIA PROTEIN; PROTEIN P53;

ARTICLE; CANCER CELL CULTURE; CANCER INHIBITION; CARCINOGENESIS; CELL CYCLE ARREST; CELL CYCLE REGULATION; CELL PROLIFERATION; CELLULAR STRESS SIGNAL; CONTROLLED STUDY; DOWN REGULATION; GENOTOXICITY; HUMAN; HUMAN CELL; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN PROTEIN INTERACTION; TRANSACTIVATION; TRANSCRIPTION REGULATION;

CELL PROLIFERATION; CELL TRANSFORMATION, NEOPLASTIC; DNA DAMAGE; GENE KNOCKDOWN TECHNIQUES; GENES, DOMINANT; HCT116 CELLS; HT29 CELLS; HUMANS; MUTANT PROTEINS; NEOPLASMS; NUCLEAR PROTEINS; PROTEIN BINDING; PROTEIN STRUCTURE, TERTIARY; PROTEIN TRANSPORT; TRANSCRIPTION FACTORS; TRANSCRIPTIONAL ACTIVATION; TUMOR CELLS, CULTURED; TUMOR SUPPRESSOR PROTEIN P53; TUMOR SUPPRESSOR PROTEINS;

EID: 66349134417     PISSN: 00085472     EISSN: 15387445     Source Type: Journal    
DOI: 10.1158/0008-5472.CAN-08-4010     Document Type: Article

References (43)

1. Meulmeester E, Jochemsen AG. p53: a guide to apoptosis. Curr Cancer Drug Targets 2008;8:87-97.
2. Strano S, Dell'Orso S, Mongiovi AM, et al. Mutant p53 proteins: between loss and gain of function. Head Neck 2007;29:488-496 (Pubitemid 46732589)
3. Sigal A, Rotter V. Oncogenic mutations of the p53 tumor suppressor: the demons of the guardian of the genome. Cancer Res 2000;60:6788-6793 (Pubitemid 32059139)
4. Strano S, Dell'Orso S, Di Agostino S, Fontemaggi G, Sacchi A, Blandino G. Mutant p53: an oncogenic transcription factor. Oncogene 2007;26:2212-2219 (Pubitemid 46536646)
5. Lang GA, Iwakuma T, Suh YA, et al. Gain of function of a p53 hot spot mutation in a mouse model of Li- Fraumeni syndrome. Cell 2004;119:861-872 (Pubitemid 40017691)
6. Olive KP, Tuveson DA, Ruhe ZC, et al. Mutant p53 gain of function in two mouse models of Li-Fraumeni syndrome. Cell 2004;119:847-860 (Pubitemid 40017690)
7. Lavin MF, Gueven N. The complexity of p53 stabilization and activation. Cell Death Differ 2006;13:941-950 (Pubitemid 43753485)
8. Bode AM, Dong Z. Post-translational modification of p53 in tumorigenesis. Nat Rev Cancer 2004;4:793-805. (Pubitemid 39331151)
9. Iwakuma T, Lozano G. Crippling p53 activities via knock-in mutations in mouse models. Oncogene 2007; 26:2177-2184 (Pubitemid 46536640)
10. Terzian T, Suh YA, Iwakuma T, et al. The inherent instability of mutant p53 is alleviated by Mdm2 or p16INK4a loss. Genes Dev 2008;22:1337-1344
11. Prives C, White E. Does control of mutant p53 by Mdm2 complicate cancer therapy? Genes Dev 2008;22: 1259-1264
12. Zimber A, Nguyen QD, Gespach C. Nuclear bodies and compartments: functional roles and cellular signalling in health and disease. Cell Signal 2004;16:1085-1104 (Pubitemid 38900512)
13. Salomoni P, Pandolfi PP. The role of PML in tumor suppression. Cell 2002;108:165-170 (Pubitemid 34161137)
14. Guo A, Salomoni P, Luo J, et al. The function of PML in p53-dependent apoptosis. Nat Cell Biol 2000;2:730-736
15. Wang ZG, Delva L, Gaboli M, et al. Role of PML in cell growth and the retinoic acid pathway. Science 1998;279: 1547-1551 (Pubitemid 28217080)
16. Trotman LC, Alimonti A, Scaglioni PP, Koutcher JA, Cordon-Cardo C, Pandolfi PP. Identification of a tumour suppressor network opposing nuclear Akt function. Nature 2006;441:523-527 (Pubitemid 44050155)
17. Gurrieri C, Capodieci P, Bernardi R, et al. Loss of the tumor suppressor PML in human cancers of multiple histologic origins. J Natl Cancer Inst 2004;96:269-279 (Pubitemid 38256272)
18. Louria-Hayon I, Grossman T, Sionov RV, Alsheich O, Pandolfi PP, Haupt Y. The promyelocytic leukemia protein protects p53 from Mdm2-mediated inhibition and degradation. J Biol Chem 2003;278:33134-33141 (Pubitemid 37055760)
19. Alsheich-Bartok O, Haupt S, Alkalay-Snir I, Saito S, Appella E, Haupt Y. PML enhances the regulation of p53 by CK1 in response to DNA damage. Oncogene 2008;27: 3653-3661
20. Fleckenstein DS, Uphoff CC, Drexler HG, Quentmeier H. Detection of p53 gene mutations by single strand conformational polymorphism (SSCP) in human acute myeloid leukemia-derived cell lines. Leuk Res 2002;26: 207-214 (Pubitemid 34037858)
21. Blandino G, Levine AJ, Oren M. Mutant p53 gain of function: differential effects of different p53 mutants on resistance of cultured cells to chemotherapy. Oncogene 1999;18:477-485 (Pubitemid 29060623)
22. Brummelkamp TR, Bernards R, Agami R. A system for stable expression of short interfering RNAs in mammalian cells. Science 2002;296:550-553 (Pubitemid 34408678)
23. Di Agostino S, Strano S, Emiliozzi V, et al. Gain of function of mutant p53: the mutant p53/NF-Y protein complex reveals an aberrant transcriptional mechanism of cell cycle regulation. Cancer Cell 2006;10: 191-202. (Pubitemid 44311070)
24. Tavalai N, Papior P, Rechter S, Leis M, Stamminger T. Evidence for a role of the cellular ND10 protein PML in mediating intrinsic immunity against human cytomegalovirus infections. J Virol 2006;80:8006-8018 (Pubitemid 44182301)
25. Bruno S, Ghiotto F, Fais F, et al. The PML gene is not involved in the regulation of MHC class I expression in human cell lines. Blood 2003;101:3514-3519 (Pubitemid 36857936)
26. Saito S, Yamaguchi H, Higashimoto Y, et al. Phosphorylation site interdependence of human p53 post-translational modifications in response to stress. J Biol Chem 2003;278:37536-37544 (Pubitemid 37175275)
27. Bolognese F, Wasner M, Dohna CL, et al. The cyclin B2 promoter depends on NF-Y, a trimer whose CCAAT-binding activity is cell-cycle regulated. Oncogene 1999; 18:1845-1853 (Pubitemid 29145852)
28. Manni I, Mazzaro G, Gurtner A, et al. NF-Y mediates the transcriptional inhibition of the cyclin B1, cyclin B2, and cdc25C promoters upon induced G2 arrest. J Biol Chem 2001;276:5570-5576 (Pubitemid 37385703)
29. Mosmann T. Rapid colorimetric assay for cellular growth and survival: application to proliferation and cytotoxicity assays. J Immunol Methods 1983;65:55-63. (Pubitemid 14203433)
30. Fogal V, Gostissa M, Sandy P, et al. Regulation of p53 activity in nuclear bodies by a specific PML isoform. EMBO J 2000;19:6185-6195
31. Bischof O, Kirsh O, Pearson M, Itahana K, Pelicci PG, Dejean A. Deconstructing PML-induced premature senescence. EMBO J 2002;21:3358-3369 (Pubitemid 34760568)
32. Bossi G, Lapi E, Strano S, Rinaldo C, Blandino G, Sacchi A. Mutant p53 gain of function: reduction of tumor malignancy of human cancer cell lines through abrogation of mutant p53 expression. Oncogene 2006;25: 304-309 (Pubitemid 43083692)
33. Shaulsky G, Goldfinger N, Rotter V. Alterations in tumor development in vivo mediated by expression of wild type or mutant p53 proteins. Cancer Res 1991;51: 5232-5237
34. Dittmer D, Pati S, Zambetti G, et al. Gain of function mutations in p53. Nat Genet 1993;4:42-46 (Pubitemid 23165910)
35. Cadwell C, Zambetti GP. The effects of wild-type p53 tumor suppressor activity and mutant p53 gain-of-function on cell growth. Gene 2001;277:15-30. (Pubitemid 32972107)
36. Imbriano C, Gurtner A, Cocchiarella F, et al. Direct p53 transcriptional repression: in vivo analysis of CCAAT-containing G2/M promoters. Mol Cell Biol 2005;25:3737-3751 (Pubitemid 40559579)
37. St Clair S, Giono L, Varmeh-Ziaie S, et al. DNA damage-induced downregulation of Cdc25C is mediated by p53 via two independent mechanisms: one involves direct binding to the cdc25C promoter. Mol Cell 2004;16: 725-736 (Pubitemid 39586531)
38. Everett RD, Rechter S, Papior P, Tavalai N, Stamminger T, Orr A. PML contributes to a cellular mechanism of repression of herpes simplex virus type 1 infection that is inactivated by ICP0. J Virol 2006;80:7995-8005. (Pubitemid 44182300)
39. Quignon F, De Bels F, Koken M, Feunteun J, Ameisen JC, de The H. PML induces a novel caspase-independent death process. Nat Genet 1998;20:259-265 (Pubitemid 28507670)
40. Xu ZX, Zhao RX, Ding T, et al. Promyelocytic leukemia protein 4 induces apoptosis by inhibition of survivin expression. J Biol Chem 2004;279:1838-1844 (Pubitemid 38084451)
41. Trecca D, Longo L, Biondi A, et al. Analysis of p53 gene mutations in acute myeloid leukemia. Am J Hematol 1994;46:304-309 (Pubitemid 24243874)
42. Li Y, Guessous F, Kwon S, et al. PTEN has tumor-promoting properties in the setting of gain-of-function p53 mutations. Cancer Res 2008;68:1723-1731
43. Longo L, Trecca D, Biondi A, et al. Frequency of RAS and p53 mutations in acute promyelocytic leukemias. Leuk Lymphoma 1993;11:405-410 (Pubitemid 24024955)